Brinker Capital Investments’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.02M | Buy |
31,944
+4,426
| +16% | +$556K | 0.03% | 468 |
|
|
2025
Q1 | $3.04M | Buy |
27,518
+1,615
| +6% | +$179K | 0.03% | 525 |
|
|
2024
Q4 | $3.54M | Sell |
25,903
-1,031
| -4% | -$141K | 0.04% | 435 |
|
|
2024
Q3 | $3.1M | Sell |
26,934
-221
| -0.8% | -$25.5K | 0.03% | 487 |
|
|
2024
Q2 | $3.74M | Sell |
27,155
-1,810
| -6% | -$249K | 0.04% | 399 |
|
|
2024
Q1 | $3.99M | Sell |
28,965
-490
| -2% | -$67.6K | 0.04% | 379 |
|
|
2023
Q4 | $3.95M | Sell |
29,455
-2,749
| -9% | -$368K | 0.05% | 365 |
|
|
2023
Q3 | $3.62M | Buy |
32,204
+3,993
| +14% | +$449K | 0.04% | 381 |
|
|
2023
Q2 | $15.3M | Sell |
28,211
-3,559
| -11% | -$1.93M | 0.16% | 125 |
|
|
2023
Q1 | $3.22M | Sell |
31,770
-1,102
| -3% | -$112K | 0.04% | 403 |
|
|
2022
Q4 | $3.93M | Sell |
32,872
-2,288
| -7% | -$273K | 0.08% | 253 |
|
|
2022
Q3 | $3.73M | Buy |
35,160
+1,587
| +5% | +$169K | 0.08% | 252 |
|
|
2022
Q2 | $3.27M | Buy |
33,573
+99
| +0.3% | +$9.65K | 0.06% | 301 |
|
|
2022
Q1 | $3.14M | Buy |
33,474
+6,434
| +24% | +$603K | 0.05% | 370 |
|
|
2021
Q4 | $2.3M | Sell |
27,040
-4,827
| -15% | -$411K | 0.03% | 520 |
|
|
2021
Q3 | $3.1M | Hold |
31,867
| – | – | 0.05% | 404 |
|
|
2021
Q2 | $3.1M | Buy |
31,867
+20,789
| +188% | +$2.02M | 0.04% | 461 |
|
|
2021
Q1 | $1.08M | Sell |
11,078
-43,886
| -80% | -$4.27M | 0.02% | 687 |
|
|
2020
Q4 | $5.27M | Buy |
54,964
+29,579
| +117% | +$2.83M | 0.08% | 297 |
|
|
2020
Q3 | $2.44M | Buy |
+25,385
| New | +$2.44M | 0.04% | 407 |
|